Androgen-accelerated bone maturation in mice is not attenuated by Faslodex, an estrogen receptor blocker

D F Gunther1, L E Underwood, A S Calikoglu

  • 1Division of Pediatric Endocrinology, University of North Carolina, Chapel Hill, NC, USA.

Bone
|May 5, 2001
PubMed

Insights

This study found that androgens directly accelerate bone maturation in mice, independent of estrogen conversion. Blocking estrogen receptors did not prevent testosterone

Area of Science:

  • Endocrinology
  • Skeletal Biology
  • Pharmacology

Background:

  • Androgens are known to accelerate bone maturation.
  • The role of estrogens, derived from androgen aromatization, in this process is not fully understood.
  • Investigating the direct effects of androgens on skeletal maturation is crucial.

Purpose of the Study:

  • To determine if estrogen blockade can inhibit testosterone-induced acceleration of skeletal maturation in immature mice.
  • To elucidate the direct role of androgens in bone maturation, separate from their conversion to estrogens.

Main Methods:

  • Immature mice were treated with testosterone propionate, Faslodex (an estrogen-blocking agent), a combination of both, or vehicle.
  • Skeletal maturation was assessed in the forepaw and lumbar spine.
  • Statistical analysis compared maturation scores between treatment groups.

Main Results:

  • Testosterone significantly accelerated bone maturation, particularly in axial bones, compared to the vehicle group.
  • Faslodex treatment did not attenuate the bone maturation effects of testosterone.
  • Mice receiving both Faslodex and testosterone showed skeletal maturation scores similar to those treated with testosterone alone.

Conclusions:

  • Androgens can directly stimulate bone maturation, likely through androgen receptors.
  • Estrogen mediation is not the primary mechanism for testosterone-accelerated skeletal maturation in this model.
  • These findings highlight the direct anabolic effects of androgens on the developing skeleton.